Infographic
DLL3-Positive vs DLL3-High: What Pathologists Need to Know
09/03/2026
This quick reference tool helps pathologists interpret and report delta-like ligand 3 (DLL3) expression using immunohistochemistry, emphasizing the importance of documenting both the percentage of positive tumor cells and staining intensity. It clarifies that DLL3-positive and DLL3-high are not interchangeable, reviews variable trial-specific thresholds, and highlights pathologists’ growing role in determining eligibility for DLL3-directed therapies and clinical trials.
© 2026 HMP Global. All Rights Reserved.
